Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
IRVINE, Calif.--(BUSINESS WIRE)--May 1, 2025--
Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.
Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA) is based on groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance (watchful waiting).
Without treatment, 1 in 10 patients experiencing symptoms of severe AS may die within five weeks. However, the symptoms of severe AS can be difficult to detect and may progress rapidly and unpredictably.
'There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend 'watchful waiting' until symptoms develop,' said Philippe Genereux, M.D., director of the structural heart program at Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey. 'As we saw in the EARLY TAVR trial, patients originally designated as asymptomatic became symptomatic in sudden and unpredictable ways, underscoring the importance of early evaluation by a heart team to improve patient outcomes and benefit the healthcare system.'
The EARLY TAVR trial was the first randomized, controlled trial designed to evaluate TAVR compared to watchful waiting for patients with asymptomatic severe AS. With a median follow-up of 3.8 years, 26.8% of the 455 patients in the TAVR arm experienced death, stroke, or unplanned cardiovascular hospitalization, compared with 45.3% of the 446 patients in the clinical surveillance arm. The data were published last year in TheNew England Journal of Medicine (NEJM), marking the ninth NEJM publication on Edwards TAVR.
'This approval is a powerful opportunity to streamline patient care and improve the efficiency of the healthcare system,' said Larry Wood, Edwards' corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical. 'We are proud to partner with leading physicians to advance our knowledge of this deadly disease with high quality science and optimize the treatment pathway for patients.'
Since its introduction more than two decades ago, SAPIEN has become the most studied valve platform, demonstrating unmatched clinical outcomes and solidifying its position as the leading choice for physicians and patients. More than 1 million patients have been treated with SAPIEN valves worldwide.
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as 'may,' 'might,' 'believe,' 'will,' 'expect,' 'project,' 'estimate,' 'should,' 'anticipate,' 'plan,' 'goal,' 'continue,' 'seek,' 'intend,' 'optimistic,' 'aspire,' 'confident' and other forms of these words and include, but are not limited to, statements made by Mr. Wood and statements regarding expected product benefits, optimization of treatment pathways, clinical outcomes, objectives, leading position, and expectations and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, EARLY TAVR, RESILIA, SAPIEN, SAPIEN 3 and SAPIEN 3 Ultra are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250501280519/en/
CONTACT: Media Contact: Heather Bukant, 949-250-2753
Investor Contact: Mark Wilterding, 949-250-6826
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL DEVICES HEALTH CLINICAL TRIALS HEALTH TECHNOLOGY
SOURCE: Edwards Lifesciences Corporation
Copyright Business Wire 2025.
PUB: 05/01/2025 08:00 AM/DISC: 05/01/2025 07:59 AM
http://www.businesswire.com/news/home/20250501280519/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
an hour ago
- Fast Company
Can healthcare go green without compromising safety?
U.S. hospitals generate nearly six million tons of waste each year, and a single patient can be responsible for more than 30 pounds a day. Much of that waste comes from the operating room (OR), which accounts for up to a third of a hospital's total output and is among the most expensive areas to manage. A large portion comes from single-use devices, packaging, and transport materials. These practices are often criticized, and not without reason. But in settings like transplantation, much of that waste is directly tied to protecting patients. I'm often asked, 'Why not make devices reusable?' or 'What about the environmental impact?' After years in the OR and working alongside transplant teams, I've asked those same questions. The answers aren't black and white, but that doesn't mean we should stop asking. Sustainability often gets reduced to packaging claims or material swaps. But the real impact lies in the systems we build around the product. That's the conversation we need to be having. Why single-use still matters Some of the industry's most criticized practices, like single-use devices, are also the least negotiable. Single-use eliminates the need for sterilization between uses, simplifies prep and cleanup, and reduces the risk of infection. The FDA permits reprocessing of certain single-use tools, but only under strict conditions. Nowhere is that margin tighter than in organ transplantation. There are no do-overs when you're handling a human organ. Transplant patients are especially vulnerable to infection due to immunosuppression, and even small lapses in sterility can lead to serious complications. Device-associated infections, from central lines, catheters, and ventilators, are among the most common and serious complications following transplant. The CDC also notes that while concerns persist about reusing single-use devices, more research is needed to define the risks. Devices that reduce infection risk and prevent complications can lead to fewer readmissions, which means fewer hospital resources used and better sustainability over time. The systems around the product Many conversations about sustainability start and stop with the product itself, whether it's recyclable, biodegradable, or made with 'green' materials. But many of the most wasteful decisions happen in how a product moves through the system that supports it. And when that system spans hospitals, suppliers, procurement teams, and legal departments, it's not built for fast change. Even when the intention is there, funding constraints, liability concerns, and the challenge of making changes across large networks often stand in the way. While a fragmented system can't solve the footprint of a single device, medical device companies still have control over how their products are moved and managed, and that's where meaningful change can start. Flying devices around the world might be fast, but it adds unnecessary emissions to an already resource-intensive process. And it's often done not because it's needed, but because it's familiar. Shifting to road transport takes more coordination, but it significantly cuts emissions and gives teams more control over when and how products arrive. What happens after delivery matters just as much. Without a plan for how products are returned, stocked, or moved, operations can shift into reaction mode. That's when waste shows up through emergency shipments, over-ordering, and unused inventory. In kidney transplant, for example, reusable machine perfusion systems have improved outcomes, but broader use has revealed logistical friction, including turnaround delays and higher discard rates. Inefficient habits tend to stay hidden until the consequences catch up. For years, private air travel has been the default in time-sensitive cases, but it comes with a steep environmental cost. At my current company, our team found that one chartered jet can emit as much carbon as manufacturing 200 single-use medical devices. With better planning, commercial flights can often meet the same clinical timelines and reduce emissions without compromising care. Sustainability has to show up in the operational decisions because if the systems around the product are wasteful, it doesn't matter how recyclable the product is. Recyclability won't negate the carbon footprint of wasteful shipping, inefficient production, or reactive inventory habits. A product isn't sustainable if it arrives on a private jet, was rushed through the supply chain, or sits unused on a shelf. Sustainability starts with better questions Healthcare won't eliminate waste entirely. But small changes matter. Reducing reliance on private air travel. Avoiding emergency shipments. Moving production closer to where products are used. None of it sounds radical. But over time, it adds up. And more often than not, it comes down to refusing to accept waste as the cost of doing business. For healthcare leaders, it's worth stepping back to examine the systems tied to a product and where a few deliberate improvements could make an impact. Not every change requires an overhaul. But the right operational shift, at the right point in the process, can reduce waste without ever touching the safety of patient care. And if enough companies commit to that kind of thinking, that's how you move an industry forward.
Newsweek
2 hours ago
- Newsweek
Churro Recall Map as Warning Issued in 13 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Camerican International is recalling boxes of their Aldi Brand Casa Mamita Churro Bites in certain states due to fears of undeclared milk. Newsweek reached out to the company via email Wednesday for comment. Why It Matters Numerous recalls have been initiated in 2025 due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA warns that people with an allergy or sensitivity to milk run the risk of a potentially life-threatening reaction if they eat the recalled churro bites. What To Know In an FDA alert on Tuesday, the churro bites filled with chocolate hazelnut cream were sold at certain Aldi locations in Alabama, Arkansas, Florida, Georgia, Iowa, Illinois, Kentucky, Louisiana, Missouri, Mississippi, North Carolina, South Carolina and Tennessee. The recalled product was packaged in a 7.05-ounce box with a lot number of 01425 and a best by date of July 14, 2025. The FDA says that there have been no reported illnesses related to this recall. Below is a map of the states impacted by the recall: What People Are Saying The FDA in the alert in part: "The recall was initiated after a consumer discovered that the milk-containing product was distributed in packaging that did not reveal the presence of milk. Subsequent investigation indicates the problem was caused by a temporary breakdown in the company's production and packaging processes that has subsequently been corrected." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. "The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall," the FDA continued. It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Customers who have purchased the recalled product are urged to return it to the original place of purchase for a full refund, the FDA says. People with any additional questions may call the company at 1-201-587-0101 on weekdays from 8:30 a.m. to 5 p.m. ET.
Bloomberg
2 hours ago
- Bloomberg
FDA to Meet Drug Approval Goals Despite Cuts, Commissioner Says
The US Food and Drug Administration will meet its drug approval targets this year despite cutting thousands of staff, the agency's commissioner said. The FDA 'will have no problem' approving new drugs on time, Marty Makary said at a Jefferies investor conference Wednesday. 'That is the top priority at the agency.'
